3 results
Primary objectives * surrogate endpoint (at interim analysis)To evaluate the efficacy of elafibranor QD for 72 weeks versus placebo on resolution of NASH without worsening of fibrosis.* Resolution of NASH is defined as the disappearance of…
Primary objective: The primary objective is to assess the efficacy and safety of nemolizumab (CD14152) after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with…
The primary objective is to assess the long-term safety of nemolizumab (CD14152) in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD).The secondary objective is to assess the long-term efficacy of nemolizumab (CD14152) in…